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Abstract: Since its first epidemic in the 1940s, retinopathy of prematurity (ROP) has been a chal-
lenging illness in neonatology. Higher than physiological oxygen levels impede the development 
of the immature retinal neuropil and vasculature. Current treatment regimens include cryotherapy, 
laser photocoagulation, and anti-VEGF agents. Unfortunately, none of these approaches can rescue 
the normal retinal vasculature, and each has significant safety concerns. The limitations of these 
approaches have led to new efforts to understand the pathological characteristics in each phase of 
ROP and to find a safer and more effective therapeutic approach. In the era of stem cell biology and 
with the need for new treatments for ROP, this review discusses the possible future use of unique 
populations of proangiogenic cells for therapeutic revascularization of the preterm retina.
Keywords: retinopathy of prematurity, ROP therapy, endothelial progenitor cells, CD34+ cells, 
endothelial colony-forming cells, oxygen-induced retinopathy
Introduction
Retinopathy of prematurity (ROP) is a major cause of blindness in children world-
wide.1,2 ROP causes approximately 14% of blindness in the US and more than 20% in 
developing countries.3 ROP only affects preterm newborns.4 Strikingly, the incidence 
of ROP has not changed significantly over the past 25 years, despite the fact that more 
resources have been devoted to the care of premature infants, such as pulse oximetry 
and surfactant antenatal steroids.1 ROP is associated with fluctuations in oxygen con-
centrations.4 The higher than physiological concentrations of oxygen that are needed 
to aid infant survival attenuate blood-vessel growth in the periphery, as well as the 
deep layers of the retina.5 Current treatments for ROP have targeted the more advanced 
stages, but none of the approaches is meant to resolve the underlying pathological 
defects, and inherently all current therapies carry adverse side effects. These therapies 
have been developed progressively with cryosurgery (1988) being developed first, then 
laser therapy (2003), and most recently intravitreal bevacizumab (2012).5
Mechanisms and current therapies for ROP
Mechanisms of vascular dysfunction
In order to understand the pathological events and how cell-based therapy works 
for ROP, the key features of normal retinal vasculature development need to be 
considered. Physiologic vasculogenesis of the retina begins in the posterior pole 
with the migration of precursor cells from the deep retina into inner layers, and 
is divided into different zones (Figure 1).1 Approximately between week 15 and 
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week 22 of gestation, these precursor cells differentiate 
into angioblasts, forming the inner vascular plexus, which 
will almost reach zone I.4 This transforming process is 
relatively independent of VEGF.1 However, after week 22, 
blood vessels are believed to grow and proliferate through 
a VEGF-dependent “budding” process and to some extent 
by angioblast transformation to vascularize peripheral 
zones II and III.1,4
Phase I, or the vasocessation phase, begins with pre-
mature birth and supplemental oxygen given to premature 
infants at supraphysiological levels. The choroid is incapable 
of autoregulation, which results in the inner retina receiv-
ing excessive levels of oxygen. At this stage, the retinal 
outer segments, the most metabolically demanding cells in 
the body, have not appeared; therefore, the retina is under 
hyperoxia.1 The high oxygen concentration in turn down-
regulates hypoxia-induced VEGF, IGF-1, and CXCL-12 
critical for normal vascularization.1,6,7 Diminished levels of 
vasogenic factors lead to delayed physiologic retinal vas-
cular development, a key characteristic of the early phase 
of human ROP.4,8
Upon the return to ambient air, it is not clearly understood 
why one population of preterm infants do not develop intrav-
itreous neovascularization (IVNV), also known as phase II or 
the neovascular phase of ROP, while the other group proceeds 
to abnormal neovascularization or serious ROP. However, it 
is appreciated that during this stage, the retina is likely to 
experience hypoxia, due to the tremendous rise in metabolism 
of the developing photoreceptor outer segments. Hypoxia 
itself can upregulate VEGF, which enhances angiogenesis 
and vasculogenesis.1
VEGF, formerly identified as “vascular permeability fac-
tor”, has increasingly been recognized to play a critical role 
in both physiologic as well as pathologic development of 
the vasculature, and is strongly associated with blood–retina 
barrier dysfuntion.4,9 In fact, one of the prominent features 
of ROP is the breakdown of the blood–retina barrier. Edema 
caused by ischemia and vascular damage may be the direct 
culprit of neural cell depletion and immune-cell activation.10 
We also know that VEGF signaling regulates ischemia-
induced hyperpermeability, endothelial cell division, and 
morphology of branching vessels.11,12 To reemphasize the 
significant role of hypoxia-induced factors (HIFs), such as 
VEGF, studies in animal models of oxygen-induced retin-
opathy (OIR) support the view that severe ROP is linked to 
different exogenous factors, including oxygen levels, inflam-
mation, and nutritional status, but all through dysregulated 
signaling cascades involving HIFs.4
Current therapies and some reported 
pitfalls
Cryosurgery, used in the multicenter CRYO-ROP trial, works 
by ablating the avascular area of the peripheral retina to reduce 
the metabolic demand and the hypoxic level of retinal cells.1 
Laser therapy was proved to be useful in the ET-ROP trial.1 
The risk of poor prognosis in approximately 90% of eyes of 
severe ROP (or type 1 ROP), as in the ET-ROP study, may 
be lowered by laser treatment.4 However, generally ablation 
therapies tend to be costly, destructive, only reduce the risk of 
blindness by 25%, and may not prevent blindness particularly 
with zone I ROP.2,13 Laser photocoagulation was found to cause 
infectious ulcerative keratitis in a subgroup of ROP infants. The 
mechanism involved postoperative corneal epithelial defects 
that led to corneal haze.14 Another study of long-term ophthal-
mological outcomes in children treated for threshold ROP by 
indirect laser photocoagulation reported that these patients had 
higher risks of strabismus, astigmatism, nystagmus, myopia, 
and lowered visual acuity compared to the control subjects, 
infants with spontaneously regressed ROP.15
Most recently established (2012) is the use of anti-VEGF 
reagents like bevacizumab intravitreally. While injection of 
anti-VEGF into the vitreous body is not as an invasive proce-
dure as the previous two therapies, the agent still raises sig-
nificant concerns, especially in long-term outcome, because 
these agents can enter the systemic circulation.16 Intravitreally 
injected anti-VEGF agents have been found to diminish VEGF 
serum levels. Ironically, research has concluded that the use of 
anti-VEGF agents may cause intravitreal angiogenesis, retinal 
detachment, and continuing avascularized retina.3 In fact, late 
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Figure 1 Schematic of retinal zones.
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reactivation of ROP post-intravitreal anti-VEGF agents has 
been reported (Table 1).2,17–20
Oxygen-induced retinopathy  
animal models
There are two commonly used OIR animal models: one using 
mice and the other rats in ROP research. It is noteworthy to 
remember that unlike humans, these species are born with 
an incomplete vascularized retina.4 In other words, for them 
the underdeveloped retinal vasculature is appropriate at 
birth. Comparison of the phases of OIR in the two models 
with human ROP stages is necessary. The early phase of 
human ROP is only reflected in the rat but not the mouse 
model, and is called phase I or “delayed physiologic retinal 
vascularization”.4 The vascular phase of stage III ROP with 
plus disease corresponds to phase II or the IVNV vaso-
proliferation phase in both models.4 A few animal models, 
such as the beagle OIR model, also have a third phase – the 
fibrovascular phase – that reflects the retinal fibroplasia 
and eventual detachment characteristics occurring during 
stages IV and V of human ROP.4 Furthermore, the mouse 
model demonstrates vaso-obliteration in phase I instead of 
“delayed physiologic retinal vascularization”.4
In vivo and in vitro studies: new 
therapeutic targets
Aligning with the approach of inhibiting pathological IVNV 
are studies that target VEGF and related factors like Ang-2 in 
angiogenesis. Ang-2, a destabilizing factor capable of con-
trolling vessel regression, is expressed by the resting endothe-
lium at low levels under physiologic conditions. However, 
both VEGF and Ang-2 are strongly upregulated by hypoxia.21 
Zhao et al21 found an interesting interaction between VEGF 
and Ang-2 that was dependent on microRNAs (miRNAs). 
Among the miRNAs screened, miR-351 was found to down-
regulate both VEGF and Ang-2 in vitro and in vivo. The 
mechanism is believed to involve competitive endogenous 
RNAs, Ang-2 and VEGF competing for miR-351 through a 
competitive endogenous RNA- and miRNA-response ele-
ments. Therefore, miR-351 can potentially become a new 
target for ablation of retinal angiogenesis in ROP as well 
as diabetic retinopathy.21 Other miRNA studies have also 
reported miR-200b being able to reduce VEGF level in STZ-
induced diabetic rats and miR-126 overexpression suppress-
ing VEGF, HIF-1α, and IGF-2 for these reasons. Therefore, 
both miR-200b and miR-126 can reduce pathological neo-
vascularization.22,23 One of the important characteristics of 
OIR models that has not been mentioned previously is micro-
gliosis. Microglia, also known as the resident macrophages 
in the central nervous system and retina, are observed to be 
activated and accumulated at sites of tissue damage to release 
proinflammatory cytokines (eg, TNFα and IL-6), which may 
contribute to vascular dysfunction.23 Infiltration of microglia 
and monocytes/macrophages has been linked to neovascular-
ization in OIR,25–27 and is also correlated with upregulation 
of proangiogenic and proinflammatory molecules, including 
metalloproteinases, FGF, and cytokines (ie, TNFα).28–30 In 
parallel with these observations, inflammation is actually 
a key difference between physiological and pathological 
angiogenesis.31 In fact, many types of proinflammatory 
cytokines, including TNFα and IL-6, exert angiogenic effects 
on the vascular endothelium via the JAK–STAT pathway.31 
For example, elimination of SOCS3, an endogenous inhibi-
tor of the JAK–STAT cascade, drives angiogenesis through 
both growth factor and cytokine secretion in tumor growth 
and OIR mice.31 Because of this phenomenon, Miyazaki 
et al used a compound called calpastatin in attempt to inhibit 
the degradation of SOCS3, and as a result they were able to 
suppress pathological angiogenesis. Nevertheless, the mecha-
nism by which calpastatin acted on endothelial cells was not 
clearly delineated.31 On the other hand, using an inhibitor of 
VEGFR2 was found to decrease the length and filopodial 
Table 1 Conventional treatments for ROP and results from clinical studies
Treatment Trials/studies Results
Cryosurgery CRYO-ROP Cryosurgery-treated eyes have better outcome in terms of letter acuity, grading 
acuity, and structural outcome of the posterior pole than controls. Results favor 
long-term efficacy and safety of cryotherapy as a treatment of ROP.17
Laser photocoagulation ET-ROP Early treatment using laser therapy for stage iii+ ROP yielded better outcomes. 
For zone i ROP, laser is only successful in 50% of cases, and can also cause 
permanent loss of peripheral visual field.2,18
Anti-vEGF reagents  
(eg, bevacizumab, ranibizumab)
Retrospective studies Cautiously used, due to potential adverse outcomes, including a higher 
incidence of retinal detachment in bevacizumab-treated versus laser therapy-
treated eyes2,19 and the occurrence of reactivation of ROP.20
Abbreviation: ROP, retinopathy of prematurity.
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number of endothelial tip cells. As a result, intravitreal but 
not intraretinal vascularization is lowered.32
Recall that ROP is associated with fluctuations in oxy-
gen concentrations, the reason being that the fluctuations 
tend to produce reactive oxygen species.4 Increases in 
lipid hydroperoxide production have been found in OIR rat 
retinas.33 Taking advantage of this observation, Saito et al33 
tested the effect of antioxidant compound N-acetylcysteine 
and the NADPH oxidase inhibitor apocynin on IVNV using 
the 50/10 OIR rat model. Results suggested that apocynin 
but not N-acetylcysteine could lessen the avascularized area 
and apoptosis in the retina, possibly involving pathways 
upstream from lipid hydroperoxide. However, neither had 
any effect on IVNV.33 In contrast, propranolol, originally used 
in the treatment of hemangiomas, was reported to be able 
to inhibit OIR neovascularization based on a mouse study 
that used nonstandard assessments (fluorescent angiography 
being unable to detect all neovascular tufts, especially those 
not fully perfused).13 To reevaluate this finding, Chen et al 
used a standard evaluation of staining vessels using specific 
endothelial cell markers to test the effect of propranolol 
delivered in three different ways – oral gavage, intraperitoneal 
injection, and subcutaneous injection – on an OIR mouse 
model. Unfortunately, the latter study proved that neither 
the doses nor route of delivery of propranolol prevented the 
development of retinopathy, and higher doses of intraperito-
neal injection even intensified pathological vascularization. 
At the molecular level, propranolol did not alter VEGF 
expression.13
Cell-based therapy: the next 
generation of ROP treatment?
Endothelial progenitor cells: early- 
outgrowth EPCs vs late-outgrowth EPCs
Unlike stem cells (SCs), progenitor cells (PCs) represent 
a larger variety of cell types, and are thought to be more 
numerous and more readily accessible. In 1997, Asahara et al 
identified endothelial PCs (EPCs).34 EPCs were thought to 
participate in angiogenesis and vasculogenesis.35 Growing 
evidence also suggests that other PCs are present in distinct 
organs in the body and contribute to tissue homeostasis, as 
well as tissue repair and regeneration.36
However, more recently the term “EPCs” has fallen out of 
use, because it is too vague in nature and actually is inaccu-
rate, as some of these subpopulations do not become endothe-
lial cells. Two types of progenitors – circulating angiogenic 
cells (CACs; also known as early-outgrowth EPCs or CD34+ 
cells) and endothelial colony-forming cells (ECFCs; or late-
outgrowth EPCs) – differ in their characteristics. CACs origi-
nated from the myelomonocytic lineage, and first become 
noticeable in culture approximately 7 days after isolation. 
These spindle-shaped cells act mainly as paracrine secre-
tors, are involved in regulation of vascular homeostasis, and 
initiate vasculogenesis without directly becoming part of the 
endothelial intima.37,38 Their counterparts, ECFCs, are circu-
lating SCs/PCs that first appear in culture after 10 days of iso-
lation, and can be harvested from umbilical cord blood, bone 
marrow, or even peripheral blood.39 ECFCs contribute to both 
angiogenesis and vasculogenesis by integrating directly into 
the developing vessels.35 They can form tubelike structures in 
vitro and perfused vessels in vivo if the cells come into con-
tact with perivascular cells like mesenchymal SCs (MSCs).40 
Patients with pulmonary arterial hypertension (PAH) have 
increased numbers of circulating ECFCs in peripheral blood; 
these ECFCs have been demonstrated to contribute to the 
vascular remodeling process in PAH.40 Interestingly, using a 
mouse model of ischemic acute kidney injury, Burger et al 
showed that human ECFCs, when administered at the time 
of reperfusion, significantly reduced macrophage infiltration, 
oxidative stress, and tubular necrosis, even without the cells 
being retained in the kidneys. Furthermore, exosomes from 
ECFCs inhibited hypoxia/reoxygenation-induced apoptosis 
of cocultured human umbilical vein endothelial cells.41
On the other hand, dysfunctional circulating progenitors 
are implicated in a number of diseases, including but not 
limited to cardiovascular pathologies, pulmonary hyperten-
sion, cancer, and diabetes mellitus.35 Based on the physiologic 
functions of these cells, it is not surprising to learn that they 
are able to promote neovascularization in early tumor forma-
tion and metastasis. In particular, one study has found that 
deguelin, a chemopreventive drug, can reduce the number of 
colony-forming units of bone marrow-derived c-Kit+/Sca-
1+ mononuclear cell migration, adhesion, and proliferation 
capability. When cocultured with endothelial cells, the treated 
EPC were less likely to form tubelike vessels, because deg-
uelin arrested the cells at the G
1
 checkpoint.42 In Moyamoya 
disease (MMD), a form of childhood stroke, the expression 
of retinaldehyde dehydrogenase 2 is significantly reduced in 
ECFCs, rendering them less efficient in forming capillary 
networks in vitro as well as in vivo.43 Teofili et al studied 
patients with myelodysplastic syndromes, and found that their 
ECFCs adhered to normal mononuclear cells more strongly 
compared to those of healthy controls.44 In PAH, ECFCs, 
located between pulmonary arterial endothelial cells, were 
found to be more proliferative than healthy ECFCs, and were 
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proposed to contribute to the proliferative pulmonary vascular 
remodeling process, the key pathological event of PAH.45
Because of such important roles under both physiologic 
and pathological conditions, these circulating progenitors 
have been an appealing topic in the field of vascular biology, 
and have been considered as the next generation of treatment 
regimen for ROP.
Stem/progenitor cells: do they have 
therapeutic potential in the retina?
Over the past few decades, studies of therapeutic SCs have 
become increasingly more popular in several different diseases, 
such as cardiovascular illnesses and osteonecrosis. SCs can be 
of embryonic origin or derived from adult organs. Although 
embryonic SCs possess tremendous potential for differentia-
tion, their use has been restricted due to ethical issues, limited 
sources, and higher risk of malignant transformation compared 
to other types of SCs.46 Fortunately, various kinds of adult 
SCs have been studied extensively and used in clinical trials 
throughout the world.47 As of today, the sources of adult SCs 
include: 1) MSCs derived from bone marrow, human umbilical 
cord blood, and other tissues, which have been demonstrated 
to have neuroprotective effects, and may differentiate into 
other cell types, including neural cells; 2) CACs, which are 
bone marrow-derived, and provide primarily paracrine sup-
port to the vasculature to foster vessel repair; 3) ECFCs, 
which are isolated from peripheral blood, cord blood, or the 
stromal vascular fraction, and can form endothelial cells; 4) 
neural precursor cells, which are multipotent cells found in the 
developing as well as the adult central nervous system and are 
heterogeneous, self-renewing, and mitotically active; and 5) 
induced pluripotent SCs, which can be generated from somatic 
cells after being treated with a defined cocktail of transcription 
factors, but tend to be time-consuming and costly.47,48
Research has aimed to use a variety of SC types to study 
drug delivery or gene therapy.47 In a 5-year follow-up study 
of femoral osteonecrosis in patients with sickle-cell disease, 
implantation of autologous bone marrow-derived mononu-
clear cells was reported to relieve pain significantly and slow 
the progressive early stages of femoral osteonecrosis. Addi-
tionally, MSCs from the same patients exhibited physiological 
characteristics that may have also played a role in the results 
observed.49 Interestingly, patients with osteonecrosis had 
 better improvements on receiving a higher amount of PCs.50
Particularly in the field of vascular biology, evidence 
has also shown promising therapeutic applications of 
SCs/PCs and their associated factors. Indeed, in a genetic 
 analysis of hypertensive rats and old mice, gene transfer 
of the longevity-associated variant BPIFB4 was able to 
enhance endothelial nitric oxide synthase and restore 
endothelial function.51 Most importantly, BPIFB4 is highly 
expressed in bloodstream CD34+ cells in long-living 
individuals. Moreover, when the BPIFB4 gene is delivered 
systemically in a murine model of peripheral ischemia, by 
recruiting additional hematopoietic SCs, the protein can 
stimulate reparative vascularization and increase perfusion 
of the ischemic muscle.51 Human placental amniotic SCs 
(HPASCs) have been shown to exert angiogenic effects 
on the retina. Kim et al found that systemic injection of 
these SCs could attenuate proliferation of endothelial 
cells through their high production of TGFβ
1
 compared 
to other MSCs. HPASCs injected intraperitoneally in an 
OIR mouse model actually migrated to the retina to reduce 
neovascularization, also by secreting TGFβ
1
, and this result 
was not seen in HPASCs treated with TGFβ
1
 small inter-
fering RNA.46 Conditioned media from MSC pretreated 
with treprostinil, a prostacyclin vasodilator indicated for 
the treatment of PAH, stimulated ECFC proliferation in 
vitro, and experiments in nude mice further demonstrated 
that treprostinil-pretreated MSCs also enhanced the 
vasculogenic properties of ECFCs. All of these effects 
were attributed to increased production of VEGF-A by 
treprostinil-pretreated MSCs.40 Another type of CAC, 
called myeloid angiogenic cells and studied by the Stitt 
Laboratory (Queen’s University Belfast), also promotes 
angiogenesis in paracrine fashion like CD34+ cells. Unlike 
CD34+ cells or ECFCs, myeloid angiogenic cells carry 
immunophenotypic signatures of M2 macrophages. Never-
theless, they also secrete angiogenic factors, especially 
IL-8, which promotes VEGF-independent phosphorylation 
of VEGFR2, and have been shown to reduce the obliterated 
central area of the retina in the OIR model.52
is therapeutic revascularization of the 
ROP retina by proangiogenic progenitor 
cells a feasible strategy for the future?
While current therapies mostly target the IVNV phase of ROP, 
scientists have become more interested in the early stage or 
phase I in OIR models. In fact, it has been seen in clinics 
that infants with zone I ROP are at higher risk of developing 
severe ROP and have poorer prognosis compared to those 
with zone II ROP.4 Therefore, restoring the vasculature of the 
immature retina is critical to reducing or preventing IVNV.
Using the OIR mouse model, we have investigated the 
concept of combination cell therapy for vascular repair. 
Specifically, we tested exogenous administration of CD34+ 
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cells with ECFCs (Figure 2). Previously, we had shown that 
healthy CD34+ cells home to areas of ischemia/reperfusion 
injury in the ROP retina and in the adult diabetic retina.53 
Human ECFCs were found to migrate to and be retained for 
7 months in nine different vascular networks when they were 
injected systemically through the tail vein of severe combined 
immunodeficient mice. The cells did not cause any infarcts 
or thrombosis.54 Although human ECFCs were also shown to 
form well-perfused vessels in vivo, they have not been tested 
in severe combined immunodeficient mice for long-term 
toxicity studies. Prasain et al examined induced pluripotent 
SC-derived ECFCs in a model of ROP, and showed that the 
cells homed to injured areas and corrected ischemia.55
Hypoxic preconditioning (HPC) can further enhance SC/
PC function. The rationale rests upon a number of observa-
tions. First, bone marrow SCs naturally reside under an 
oxygen tension of approximately 1%–7%,56,57 and long-term 
repopulating hematopoietic SCs in the mouse also exist under 
hypoxic conditions.58 It has been known that when the oxygen 
level falls below 5%, HIFs will be activated and continue 
to rise in concentration directly with the decreased level of 
oxygen.59 In a hypoxic environment, HIF-1α and HIF-2α are 
protected from ubiquitination and proteasomal degradation, 
and as a result HIF-1α and HIF-2α concentrations rise, along 
with other hypoxia-induced messenger RNAs, including 
those that are important for angiogenesis, apoptosis, and 
energy metabolism.60–63 In particular, HIF-1α can regulate 
MSC proliferation by increasing TWIST expression, and con-
sequently downregulates the inhibitory effect of the E2A–p21 
pathway on senescence to enhance proliferation.
In addition, HPC causes reduced apoptosis and thereby 
increases capacity of implanted MSCs in fixing myocardial 
infarction or diabetic cardiomyopathy. HPC also promotes 
angiogenesis and vascularization through paracrine  factors.64–66 
When cultured in a hypoxic environment, human cord blood-
derived CD34+ cells can reverse their senescence and become 
more proliferative again by higher HIF-1α-induced TWIST 
expression.67 It has been shown that the population-doubling 
time of marrow-isolated adult multilineage-inducible cells 
is decreased as oxygen tension is lowered, with the optimal 
oxygen tension being 3%.68 Therefore, there is ample evidence 
that preconditioning SCs may improve their viability and func-
tion when injected into an adverse and diseased environment, 
such as ROP or diabetic retina.
Combination cell therapy
A combination of ECFCs and CD34+ cells in nude mice was 
seen to promote revascularization in a synergistic manner in 
response to acute vascular injury.69 As shown in the schematic 
in Figure 3, there is considerable evidence to suggest that 
several SC–PC combinations can serve to enhance vascu-
lar repair. There are different populations that can become 
pericytes or smooth-muscle cells, and these include adipose-
derived MSCs (ASC) and bone marrow-derived MSCs.70 
ECFCs can serve as a source of endothelial cells, and can 
easily be combined with either MSC population. As shown 
in Figure 4, the combined use of CD34+ cells with ECFCs 
shows improved homing compared to either cell type alone 
in the ROP model, suggesting that CD34+ cells are likely 
secreting factors that enhance ECFC function.
Moreover, understanding the molecular factors influ-
encing these cells will likely reveal potential modulators of 
vascular formation and remodeling. Interestingly, despite the 
aforementioned important angiogenic property of VEGF, in 
the absence of IGF-1, VEGF is not sufficient to drive normal 
development of retinal vasculature. In fact, low levels of 
IGF-1 are linked to the pathogenesis of ROP.71 However, aber-
rant expression of IGF-1 can also contribute to pathological 
neovascularization.72
It is believed that IGF-1 exerts its effects via interactions 
with IGFBPs. Among these, IGFBP-3 is found to promote 
A B
C D
SVP SVP
SVPSVP
DVP DVP
Figure 2 injection of ECFCs on P5 stimulates the development of the deep vascular 
plexus in the OiR pups prior to return to normoxic conditions on postnatal day 12.
Notes: Confocal images from flat-mounted retinas from OIR pups injected on 
postnatal day 5 and euthanized on postnatal day 12. The four panels show a z-stack of 
confocal images from retinas of OiR mouse pups on the left, and rotated (90°) images 
of 3-D projections of the retinas on the right showing a cross section of the retina 
(vitreous, left side; choroid, right side. CD34+ cells are in blue. (A) Retina from saline-
injected pup, (B) from CD34+ cell-injected mouse, (C) from ECFC-injected mouse, 
and (D) from CD34+ cell- and ECFC-injected mouse. Blood vessels are stained with 
collagen iv antibody. ECFCs express GFP. ECFC incorporated into blood vessels are 
yellow. Scale bars, 50 µm. Original images were captured with either 10× (A, C) or 
20× objective (B, C).
Abbreviations: ECFCs, endothelial colony-forming cells; OiR, oxygen-induced 
retinopathy; SVP, superficial vascular plexus; DVP, deep vascular plexus.
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migration of CD34+ cells and differentiation of CD34+ 
cells to ECs; both are essential for endothelial repair after 
ischemic injury in the OIR model. The remodeling process 
occurs through downregulation of CD133 and upregulation 
of endothelial nitric oxide synthase expression.71 Intriguingly, 
proliferating ECs that express IGFBP-3 have been shown 
to be protected from hyperoxia-induced vascular ablation 
while reducing preretinal neovascularization.73,74 As already 
stated, restoration of a healthy endothelium not only involves 
CD34+ cells and ECFCs but also other bone marrow-derived 
cells, such as pericytes and astrocytes, for their supportive 
functions. Further investigation reveals that IGFBP-3 indeed 
enhances differentiation of bone marrow-derived cells into 
pericytes and astrocytes. Moreover, IGFBP-3 reduces peri-
cyte apoptosis while attenuating activated microglia cells 
during the hypoxic phase of the OIR model.74
To summarize, angiogenesis is a highly dynamic and 
finely tuned process that engages both cellular and paracrine 
factors. By manipulating the right balance of key molecular 
factors, we will enable the angiogenic cells (ie, CD34+ cells, 
ECFCs, and supporting cells like pericytes) to fulfill their 
functions.
Conclusion
ROP continues to be a great concern, particularly in devel-
oping countries, where regulating oxygenation of preterm 
infants is not yet possible. Considering the currently available 
treatment options for ROP, new innovative approaches for 
better ROP therapies are definitely needed. More insights 
are being gained into the pathophysiology of the  developing 
 neuronal and vascular retina, and this knowledge will 
 facilitate the translation of basic studies into clinical practice. 
PCs/SCs have been used therapeutically in other vascular 
diseases, providing a framework for their study in animal 
MSC
RBC
ASC
Astrocyte
Endothelial
cellPericyte
Ischemic injury
Vaso-
occlusion
Interneuron
Repair
iPS-ECFCs
CD34+ cell
Figure 3 ischemic injury on retinal micro-blood vessel results in loss of pericytes and endothelial cells and vaso-occlusion. 
Notes: MSCs and ASCs differentiate into pericytes. Cell-surface receptors on intravitreally injected iPS-ECFCs or ECFCs interact with paracrine-released factors from 
CD34+ cells to differentiate into endothelial cells.
Abbreviations: MSCs, mesenchymal stem cells; RBC, red blood cells; ASCs, adipose-derived stem cells; iPS-ECFCs, induced pluripotent stem endothelial colony-forming 
cells.
CD34+ cell
CD34+ cell
CD34+ cell
CD34+ cell
iPS-ECFC
ECFC
ECFC
MSC
Endothelial
cell
ASC
MSC
Blood
vessel
Pericyte
Figure 4 Combination of various cell types that repair damage to ischemia-derived 
injuries.
Abbreviations: iPS-ECFC, induced pluripotent stem endothelial colony-forming 
cell; MSC, mesenchymal stem cell; ASC, adipose-derived stem cell; ECFC, endothelial 
colony-forming cells.
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models of retinal disease and eventually for their translational 
to ocular clinical trials. To accelerate the translational process, 
more preclinical work defining the safety and function of each 
SC/PC population alone and in combination is needed.
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